AC220
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed AML
Conditions
Relapsed AML, Refractory AML
Trial Timeline
Feb 1, 2016 → Nov 13, 2018
NCT ID
NCT02675478About AC220
AC220 is a phase 1 stage product being developed by Daiichi Sankyo for Relapsed AML. The current trial status is completed. This product is registered under clinical trial identifier NCT02675478. Target conditions include Relapsed AML, Refractory AML.
What happened to similar drugs?
2 of 20 similar drugs in Relapsed AML were approved
Approved (2) Terminated (2) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02675478 | Phase 1 | Completed |
| NCT01565668 | Phase 2 | Completed |
| NCT01468467 | Phase 1 | Completed |
| NCT00462761 | Phase 1 | Completed |
Competing Products
20 competing products in Relapsed AML